Novosanis Overview

  • Founded
  • 2013
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 5
Employees
  • Latest Deal Type
  • M&A

Novosanis General Information

Description

Developer of medical devices intended to improve the quality of diagnostics tests as well as the accuracy of drug delivery. The company's devices range from injection appliances to in vitro diagnostic accessories that are suited for collection of first void urine which provides an improved diagnosis of sexually transmitted infections and cancer, enabling physicians to treat their patients in an enhanced way.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Medical Supplies
Other Industries
Other Devices and Supplies
Parent Company
Primary Office
  • Bijkhoevelaan 32c
  • 2110 Wijnegem
  • Belgium
+32 03 000 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Novosanis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 04-Jan-2019 00.000 Completed Generating Revenue
6. Angel (individual) 10-Jul-2018 00.000 00.000 00.000 Completed Generating Revenue
5. Grant 04-Apr-2017 00.000 Completed Generating Revenue
4. Angel (individual) 26-Jan-2017 00000 00.000 00.000 Completed Generating Revenue
3. Grant 15-Sep-2015 00000 Completed Generating Revenue
2. Grant 13-Aug-2014 $336K $636K Completed Generating Revenue
1. Seed Round 19-Jul-2013 $636K $636K 00.000 Completed Generating Revenue
To view Novosanis’s complete valuation and funding history, request access »

Novosanis Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class B 00,000 000.00 000.00 00 000.00 0.000
Class A 00,000 000.00 000.00 00 000.00 0.000
Class B 0,000 000.00 000.00 00 000.00 0.000
Class A 0,000 000.00 000.00 00 000.00 0.000
Class B 0,000 000.0 000.0 00 000.0 0.000
Class A 000 000.0 000.0 00 000.0 0.000
Class B 00,000 000.00 000.00 00 000.00 0.00
Class A 0,000 000.00 000.00 00 000.00 0.000
Class B 18,000 $24.97 $24.97 1x $24.97 8.82%
Class B 20,000 $28.43 $28.43 1x $28.43 9.8%
To view Novosanis’s complete cap table history, request access »

Novosanis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of medical devices intended to improve the quality of diagnostics tests as well as the accuracy of drug delive
Medical Supplies
Wijnegem, Belgium
5 As of 2016
00.000
000000&0 00.000

00000000

m dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui
0000000000 000000000
Saint Louis, MO
00 As of 0000
0000
000000000 - 0000

00000000

or sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna
00000 0000000 000 00000000
Pleasanton, CA
00 As of 0000
000.00
00.00 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Novosanis Competitors (21)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BacterioScan Venture Capital-Backed Saint Louis, MO 00 0000 000000000 - 0000
000000000 (00000 0 Venture Capital-Backed Pleasanton, CA 00 000.00 00000000000 000.00
000000000000 Private Equity-Backed Puteaux, France 000 000.00 000000000000
000000000 Venture Capital-Backed Dublin, Ireland 00 000.00 0000000000 0 000.00
0000000000 0000000 Corporation Tucson, AZ 000 000.00 0000000000 000.00
You’re viewing 5 of 21 competitors. Get the full list »

Novosanis Patents

Novosanis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3019486-A1 Injection device Pending 01-Apr-2016 00000000
EP-3436111-A1 Injection device Pending 01-Apr-2016 00000000
JP-2019510574-A Injection device Pending 01-Apr-2016 00000000 0
US-20190111218-A1 Injection device Pending 01-Apr-2016 00000000
GB-201216079-D0 Liquid sampler, kit of parts, and method for assembly Withdrawn 10-Sep-2012 A61B10/007
To view Novosanis’s complete patent history, request access »

Novosanis Executive Team (6)

Name Title Board Seat Contact Info
Vanessa Vankerckhoven Ph.D Co-Founder, Chief Executive Officer & Board Member
Alex Vorsters Ph.D Scientific Advisor & Member of Scientific Advisory Board
Koen Beyers Co-Founder, Chief Technology Officer & Board Member
You’re viewing 3 of 6 executive team members. Get the full list »

Novosanis Board Members (7)

Name Representing Role Since
Koen Beyers Self Co-Founder, Chief Technology Officer & Board Member 000 0000
Luc Kindt Novosanis Board Member & Advisor, Sales 000 0000
Philip De Mulder Novosanis Board Member 000 0000
Stijn Verwulgen Novosanis Member of Board of Director & Scientific Advisor 000 0000
Vanessa Vankerckhoven Ph.D Novosanis Co-Founder, Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Novosanis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novosanis Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Horizon 2020 Government Minority 000 0000 000000 0
Taste Westerlund Venture Capital Minority 000 0000 000000 0
To view Novosanis’s complete investors history, request access »